Revelation Biosciences (REVB) Accounts Payables (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Accounts Payables of $577501.0 for Q4 2025, down 26.3% year-over-year from $783621.0 in Q4 2024, and down 44.2% quarter-over-quarter from $1.0 million in Q3 2025.
Revelation Biosciences (REVB) Accounts Payables (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Accounts Payables for 6 consecutive years, with $577501.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables fell 26.3% year-over-year to $577501.0; the TTM figure through Dec 2025 stood at $577501.0 (down 26.3% YoY), while the FY2025 annual figure was $577501.0, down 26.3% from the prior year.
- Accounts Payables declined to $577501.0 in Q4 2025 per REVB's latest filing, from $1.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $3.1 million in Q3 2024 and bottomed at $383635.0 in Q1 2021.
- Historically, Accounts Payables has averaged $1.1 million across 5 years, with a median of $915170.5 in 2022.
- Annual changes were most pronounced in 2021 — Accounts Payables surged 1665.55% — and 2022, when it slumped 70.76%.
- Revelation Biosciences' Accounts Payables stood at $596261.0 in 2021, then declined by 7.05% to $554205.0 in 2022, then surged by 145.38% to $1.4 million in 2023, then tumbled by 42.38% to $783621.0 in 2024, then slipped by 26.3% to $577501.0 in 2025.
- Business Quant data shows REVB's Accounts Payables at $577501.0 in Q4 2025, $1.0 million in Q3 2025, and $828894.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 35.57 Mn |
| 10 | Revelation Biosciences | 4.08 Mn | -7.42 Mn | - | 931,093.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 931,093.00 |
| Dec 31, 2025 | 577,501.00 |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 828,894.00 |
| Mar 31, 2025 | 625,058.00 |
| Dec 31, 2024 | 783,621.00 |
| Sep 30, 2024 | 3.13 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 913,866.00 |
| Mar 31, 2023 | 705,089.00 |
| Dec 31, 2022 | 554,205.00 |
| Sep 30, 2022 | 466,084.00 |
| Jun 30, 2022 | 916,475.00 |
| Mar 31, 2022 | 1.46 Mn |
| Dec 31, 2021 | 596,261.00 |
| Sep 30, 2021 | 1.59 Mn |
| Jun 30, 2021 | 1.08 Mn |